There are 3161 resources available
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01